Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
Eligibility
Participation Requirements
Sex: All
Minimum Age: 9
Healthy Volunteers: f
View:
• patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
Locations
Other Locations
Egypt
Reham Essam
RECRUITING
Zagazig
Contact Information
Primary
Reham Essam, MD
rereessam22@gmail.com
+201097709477
Backup
Reham Essam, MD
rekfarid@medicine.zu.edu.eg
+201097709477
Time Frame
Start Date: 2022-04-03
Estimated Completion Date: 2025-12-06
Participants
Target number of participants: 162
Treatments
Experimental: Candida antigen group
54 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Experimental: Bivalent HPV vaccine
54 patients will be treated with the Bivalent HPV vaccine. All patients will be directly injected with the vaccine into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Experimental: both agents group
54 patients will be treated with Both agents at the same session. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Related Therapeutic Areas
Sponsors
Leads: Zagazig University